CY1122799T1 - Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης - Google Patents

Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Info

Publication number
CY1122799T1
CY1122799T1 CY20201100163T CY201100163T CY1122799T1 CY 1122799 T1 CY1122799 T1 CY 1122799T1 CY 20201100163 T CY20201100163 T CY 20201100163T CY 201100163 T CY201100163 T CY 201100163T CY 1122799 T1 CY1122799 T1 CY 1122799T1
Authority
CY
Cyprus
Prior art keywords
ethoxy
processes
preparation
methanosulfonylethylamine
methoxyphenyl
Prior art date
Application number
CY20201100163T
Other languages
English (en)
Inventor
Jasti VENKATESWARALU
Chinnapillai Rajendiran
Nallamaddi Ravikumar Reddy
Terrence Joseph Connolly
Alexander L. Ruchelman
Jeffrey Eckert
Anthony Joseph Frank
Original Assignee
Amgen (Europe) GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122799(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen (Europe) GmbH filed Critical Amgen (Europe) GmbH
Publication of CY1122799T1 publication Critical patent/CY1122799T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Στο παρόν παρέχονται νέες διεργασίες για την παρασκευή ενδιαμέσων αμινοσουλφόνης για τη σύνθεση της 2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολινο-1,3-διόνης, που είναι χρήσιμη για την πρόληψη ή τη θεραπεία νόσων ή καταστάσεων που σχετίζονται με ένα μη φυσιολογικά υψηλό επίπεδο ή δραστικότητα του ΤΝF-α. Περαιτέρω παρέχονται στο παρόν διεργασίες για την εμπορική παραγωγή της (S)-1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμίνης.
CY20201100163T 2012-02-21 2020-02-21 Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης CY1122799T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21
PCT/US2013/026780 WO2013126360A2 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine
EP13706898.7A EP2817288B1 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine

Publications (1)

Publication Number Publication Date
CY1122799T1 true CY1122799T1 (el) 2021-05-05

Family

ID=47755073

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100742T CY1121833T1 (el) 2012-02-21 2019-07-11 Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης
CY20201100163T CY1122799T1 (el) 2012-02-21 2020-02-21 Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100742T CY1121833T1 (el) 2012-02-21 2019-07-11 Διεργασιες για την παρασκευη (s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης

Country Status (36)

Country Link
US (3) US9187417B2 (el)
EP (4) EP3312156B1 (el)
JP (1) JP2015509496A (el)
KR (1) KR101993248B1 (el)
CN (3) CN112812044B (el)
AR (2) AR090100A1 (el)
AU (1) AU2013203283B2 (el)
BR (3) BR122021020046B1 (el)
CA (1) CA2864517A1 (el)
CO (1) CO7061071A2 (el)
CR (1) CR20140395A (el)
CY (2) CY1121833T1 (el)
DK (2) DK3378850T3 (el)
ES (4) ES2735801T3 (el)
HK (1) HK1205501A1 (el)
HR (2) HRP20191249T1 (el)
HU (2) HUE048412T2 (el)
IL (3) IL234135A (el)
IN (1) IN2014DN06740A (el)
LT (2) LT3378850T (el)
MX (2) MX350731B (el)
MY (1) MY168296A (el)
NI (1) NI201400093A (el)
NZ (1) NZ628028A (el)
PH (1) PH12014501865A1 (el)
PL (2) PL3378850T3 (el)
PT (2) PT3312156T (el)
RS (2) RS59071B1 (el)
RU (1) RU2632875C2 (el)
SG (1) SG11201405035XA (el)
SI (2) SI3312156T1 (el)
TR (1) TR201910430T4 (el)
TW (1) TW201336815A (el)
UA (1) UA116773C2 (el)
WO (1) WO2013126360A2 (el)
ZA (1) ZA201405892B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
NZ628329A (en) 2013-06-17 2017-12-22 Celgene Corp Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (el) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
EP3143004B1 (en) 2014-05-11 2020-09-02 Mapi Pharma Limited Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
CN107922326A (zh) * 2015-06-09 2018-04-17 雷迪博士实验室有限公司 阿普斯特的制备方法及其中间体
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
EP3356327A1 (en) 2015-09-29 2018-08-08 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10399942B2 (en) 2015-11-19 2019-09-03 Alembic Pharmaceuticals Limited Process and novel polymorphic form of Apremilast
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
WO2017179065A1 (en) 2016-04-15 2017-10-19 Davuluri Ramamohan Rao Improved process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
DE102017200731A1 (de) 2016-11-10 2018-05-17 Sms Group Gmbh Verfahren zum Herstellen eines metallischen Bandes in einer Gießwalzanlage
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
PT3606907T (pt) 2017-04-04 2021-04-01 Quim Sintetica S A Compostos de beta-aminossulfona racémica
HUE051684T2 (hu) 2017-04-04 2021-03-29 Quim Sintetica S A Racém béta-aminoszulfon vegyületek rezolválása
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 （s）-1-(3-乙氧基-4-甲氧基苯基)-2-（甲磺酰基）乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
EA001207B1 (ru) 1996-03-22 2000-12-25 Дюпон Фармасьютикалз Компани Способ получения r-альфа-пропил-пиперониламина и его аналогов, промежуточные продукты, используемые в этом способе
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
JP5269281B2 (ja) 2002-12-30 2013-08-21 セルジーン コーポレイション フルオロアルコキシ置換１，３−ジヒドロイソインドリル化合物およびそれらの医薬としての使用
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
CA2711576C (en) * 2008-01-25 2016-06-21 High Point Pharmaceuticals, Llc Tricyclic compounds as inhibitors of tnf-.alpha. synthesis and as pde4 inhibitors
PL2334639T3 (pl) * 2008-09-10 2013-08-30 Celgene Corp Sposoby wytwarzania związków aminosulfonowych
ES2469849T3 (es) * 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
ES2451350T3 (es) 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Also Published As

Publication number Publication date
US9187417B2 (en) 2015-11-17
CY1121833T1 (el) 2020-10-14
LT3378850T (lt) 2020-04-10
SG11201405035XA (en) 2014-09-26
EP3312156A1 (en) 2018-04-25
CA2864517A1 (en) 2013-08-29
MX350731B (es) 2017-09-15
PL3378850T3 (pl) 2020-07-27
WO2013126360A2 (en) 2013-08-29
ES2971710T3 (es) 2024-06-06
EP3312156B1 (en) 2019-06-05
WO2013126360A3 (en) 2013-10-31
NI201400093A (es) 2016-11-30
ES2675168T3 (es) 2018-07-09
CR20140395A (es) 2014-11-17
PH12014501865B1 (en) 2014-11-17
ZA201405892B (en) 2015-11-25
MX344190B (es) 2016-12-08
US20170129852A1 (en) 2017-05-11
AU2013203283B2 (en) 2015-11-26
JP2015509496A (ja) 2015-03-30
KR20140126389A (ko) 2014-10-30
HUE044192T2 (hu) 2019-10-28
SI3378850T1 (sl) 2020-07-31
PH12014501865A1 (en) 2014-11-17
RU2632875C2 (ru) 2017-10-11
AU2013203283A1 (en) 2013-09-05
HRP20191249T1 (hr) 2019-10-18
BR122021020040B1 (pt) 2022-05-31
US9688623B2 (en) 2017-06-27
IL273050A (en) 2020-04-30
IL234135A (en) 2017-06-29
EP3378850B8 (en) 2020-03-04
RS59071B1 (sr) 2019-09-30
CN107033042A (zh) 2017-08-11
EP3378850A1 (en) 2018-09-26
BR122021020046B1 (pt) 2022-05-31
EP2817288B1 (en) 2018-05-30
RS60036B1 (sr) 2020-04-30
US20160031808A1 (en) 2016-02-04
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
PT3378850T (pt) 2020-03-06
SI3312156T1 (sl) 2019-09-30
US9586897B2 (en) 2017-03-07
ES2773686T3 (es) 2020-07-14
DK3378850T3 (da) 2020-03-16
EP3378850B1 (en) 2020-01-08
HRP20200245T1 (hr) 2020-05-15
MY168296A (en) 2018-10-23
HUE048412T2 (hu) 2020-07-28
US20130217918A1 (en) 2013-08-22
TW201336815A (zh) 2013-09-16
EP2817288A2 (en) 2014-12-31
ES2735801T3 (es) 2019-12-20
PL3312156T3 (pl) 2019-10-31
EP3702347B1 (en) 2023-11-08
CN112812044B (zh) 2023-05-30
IN2014DN06740A (el) 2015-05-22
UA116773C2 (uk) 2018-05-10
NZ628028A (en) 2016-03-31
AR090100A1 (es) 2014-10-22
DK3312156T3 (da) 2019-07-22
CO7061071A2 (es) 2014-09-19
CN104245668B (zh) 2017-05-17
CN112812044A (zh) 2021-05-18
PT3312156T (pt) 2019-07-19
AR117963A2 (es) 2021-09-08
CN104245668A (zh) 2014-12-24
RU2014138037A (ru) 2016-04-10
KR101993248B1 (ko) 2019-06-26
IL252459A0 (en) 2017-07-31
BR112014020444B1 (pt) 2021-12-07
IL252459B (en) 2020-03-31
EP3702347A1 (en) 2020-09-02
BR112014020444A2 (pt) 2020-10-27
TR201910430T4 (tr) 2019-08-21
HK1205501A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
CY1122799T1 (el) Διεργασιες για την παρασκευη(s)-1-(3-αιθοξυ-4μεθοξυφαινυλ)-2-μεθανοσουλφονυλαιθυλαμινης
AU2019232913A1 (en) Methods and processes for non-invasive assessment of genetic variations
CY1124988T1 (el) Μεθοδοι παρασκευης νεων αναστολεων idh1
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CA2877331C (en) Methods and processes for non-invasive assessment of genetic variations
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201790695A1 (ru) Иммуномодуляторы
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
TN2014000063A1 (en) Kinase inhibitor polymorphs
GT201500069A (es) Piridinonas bicìclicas novedosas
CR20110554A (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil-piperazina
RU2011134931A (ru) Штамм enterococcus, используемый для приготовления кисломолочных напитков
UY33976A (es) Derivados de pirazolo-pirimidina.
CU20110220A7 (es) Espiro-epóxidos como productos intermedios
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY34072A (es) Derivados sustituidos de indol
IT1397233B1 (it) Procedimento migliorativo per la sintesi del mono-acetil ganciclovir, intermedio chiave per la sintesi del valganciclovir.